Funding Briefs

Stars Wars, Inner Space Style Congress apparently is very interested in the potential medical applications of free-electron laser (FEL) technology, which heretofore has primarily been under development in connection with Strategic Defense Initiative use, but is increasingly being regarded as a possible future weapon against such viruses as those causing AIDS and herpes. The new budget for fiscal 1989 (which went into effect Oct. 1) included an extra $17 million for SDI stipulating that the all

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Congress apparently is very interested in the potential medical applications of free-electron laser (FEL) technology, which heretofore has primarily been under development in connection with Strategic Defense Initiative use, but is increasingly being regarded as a possible future weapon against such viruses as those causing AIDS and herpes. The new budget for fiscal 1989 (which went into effect Oct. 1) included an extra $17 million for SDI stipulating that the allotment be used solely for EEL medical research. The Pentagon has already started to solicit proposals for two grant programs that would support university research on the technology. Proposals are beginning to trickle in, according to Air Force Captain Charles Houston, who directs the SDI Qrganization’s medical EEL program. Recipients are expected to be named before year’s end.

“We’re developing low-weight, low-cost [EEL] systems to be used in more locations,” says Houston. Prototypes currently exist at the University of California, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies